Cited by 559Bone health and osteoporosis researchMenopause: Health Impacts and TreatmentsBone health and treatments

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy

Van Staa, T. P., Laan, R. F., Barton, I. P., Cohen, S., Reid, D. M., Cooper, C.·2003·Arthritis & Rheumatism

Open this paper in CoChat — free account

Abstract

OBJECTIVE: To evaluate predictors of vertebral fractures, including a threshold for bone mineral density (BMD), in patients receiving oral glucocorticoids (GCs). METHODS: Data were obtained from 2 randomized clinical trials (prevention and treatment trials of risedronate) using similar methods, but different inclusion criteria were applied with regard to prior exposure to GCs. Predictors of vertebral fracture in the placebo group were identified using Cox regression with forward selection. The BMD threshold analysis involved a comparison of the 1-year fracture risk in postmenopausal women receiving placebo in the GC trials with that in postmenopausal women not taking GCs in 3 other trials. RESULTS: The study population comprised 306 patients with baseline and 1-year followup data on vertebral fractures (111 receiving placebo and 195 receiving risedronate). In the placebo group, the statistically significant predictors of incident fracture were the baseline lumbar spine BMD (for each 1-point decrease in T score, relative risk [RR] 1.85, 95% confidence interval [95% CI] 1.06-3.21) and the daily GC dose (for each 10-mg dose increase, RR 1.62, 95% CI 1.11-2.36). In the BMD threshold analysis, compared with nonusers of GCs, patients receiving GCs were younger, had a higher BMD at baseline, and had fewer prevalent fractures; nevertheless, the risk of fracture was higher in the GC users compared with nonusers (adjusted RR 5.67, 95% CI 2.57-12.54). The increased risk of fracture was observed in GC users regardless of whether osteoporosis was present. CONCLUSION: The daily, but not cumulative, GC dose was found to be a strong predictor of vertebral fracture in patients receiving GCs. At similar levels of BMD, postmenopausal women taking GCs, as compared with nonusers of GCs, had considerably higher risks of fracture.

Integrity signals

Registry

Crossref · 10.1002/art.11283

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Vertebral fracture assessment using a semiquantitative technique
Genant, H. K., Wu, C. Y., van Kuijk, C., & Nevitt, M. C. (1993) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650080915 · Cited by 3,691
Effects of Risedronate Treatment on Vertebral and Nonvertebral Fractures in Women With Postmenopausal Osteoporosis<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>
Harris, S. T. (1999) · JAMA · doi:10.1001/jama.282.14.1344 · Cited by 2,475
Effect of Risedronate on the Risk of Hip Fracture in Elderly Women
McClung, M. R., Geusens, P., Miller, P. D., Zippel, H., Bensen, W. G., Roux, C., Adami, S., Fogelman, I., Diamond, T., Eastell, R., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102013440503 · Cited by 1,918
Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone.
Weinstein, R. S., Jilka, R. L., Parfitt, A. M., & Manolagas, S. C. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2799 · Cited by 1,753 · cited 3×
“Osteocyte apoptosis is prevalent in GC-induced osteoporosis (24), and preliminary results of an animal study demonstrated that osteocyte viability was an important determinant of bone strength independent of BMD (25).”
BackgroundResult
Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis
Reginster, J.-Y., Minne, H. W., Sorensen, O. H., Hooper, M., Roux, C., Brandi, M. L., Lund, B., Ethgen, D., Pack, S., Roumagnac, I., et al. (2000) · Osteoporosis International · doi:10.1007/s001980050010 · Cited by 1,580
Use of Inhaled Corticosteroids and Risk of Fractures
van Staa, T. P., Leufkens, H. G. M., & Cooper, C. C. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.3.581 · Cited by 1,297
Self-citation
The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis
Staa, T. P. V., Staa, T. P. V., Staa, T. P. V., Leufkens, H. G. M., & Cooper, C. (2002) · Osteoporosis International · doi:10.1007/s001980200108 · Cited by 1,294
Self-citation
Use of oral corticosteroids and risk of fractures
Van Staa, T. P., Leufkens, H. G. M., Abenhaim, L., Zhang, B., & Cooper, C. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.6.993 · Cited by 1,263
Self-citation
Dose-Response and Trend Analysis in Epidemiology
Greenland, S. (1995) · Epidemiology · doi:10.1097/00001648-199507000-00005 · Cited by 1,086
Recommendations for the prevention and treatment of glucocorticoid‐induced osteoporosis
American College of Rheumatology task force on Osteoporosis guidelines (1996) · Arthritis & Rheumatism · doi:10.1002/art.1780391104 · Cited by 848

Flagged first, then by citations

Show all 29 references

Research works printed but not linked: 3

1996, SAS/GRAPH software: reference version 6
Johnell O, 2002, Oral corticosteroids increase fracture risk independently of BMD, Osteoporos Int, 13, S14
Weinstein RS, 2002, Preservation of osteocyte viability by bisphosphonates contributes to bone strength in glucocorticoid‐treated mice independently of BMD: an unappreciated determinant of bone strength, J Bone Miner Res, 17, S156

Sorted by citations

Items 301–400 of 556

Glucocorticoids employ the monomeric glucocorticoid receptor to potentiate vitamin D 3 and parathyroid hormone‐induced osteoclastogenesis
Conaway, H. H., Henning, P., Lie, A., Tuckermann, J. P., & Lerner, U. H. (2019) · The FASEB Journal · doi:10.1096/fj.201802729rrr · Cited by 17
High fracture risk patients with glucocorticoid-induced osteoporosis should get an anabolic treatment first
Lespessailles, É., & Chapurlat, R. D. (2020) · Osteoporosis International · doi:10.1007/s00198-020-05568-w · Cited by 17
Skeletal effects of short-term exposure to dexamethasone and response to risedronate treatment studied in vivo in rabbits by magnetic resonance micro-imaging and spectroscopy
Takahashi, M., Saha, P. K., & Wehrli, F. W. (2006) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-006-0712-1 · Cited by 17
Overview of Pathogenesis
Reid, I. R. (2013) · Primer on the metabolic bone diseases and disorders of mineral metabolism · doi:10.1002/9781118453926.ch41 · Cited by 17
Effect of alendronate on bone metabolic indices and bone mineral density in patients treated with high-dose glucocorticoid: a prospective study
Kaji, H., Kuroki, Y., Murakawa, Y., Funakawa, I., Funasaka, Y., Kanda, F., & Sugimoto, T. (2010) · Osteoporosis International · doi:10.1007/s00198-009-1110-z · Cited by 16
Bisphosphonates and glucocorticoid-induced osteoporosis: Efficacy and tolerability
Lespessailles, É. (2012) · Joint Bone Spine · doi:10.1016/j.jbspin.2012.08.005 · Cited by 16
Bone strength and management of postmenopausal fracture risk with antiresorptive therapies: considerations for women’s health practice
Elsaid, S., Frame, H., Ho, M., Mackinnon, E., Brown, J. P., & Cheung, A. M. (2016) · International Journal of Women s Health · doi:10.2147/ijwh.s112621 · Cited by 17
The Safety of Low-Dose Glucocorticoids in Rheumatic Diseases: Results from Observational Studies
Hwang, Y. G., & Saag, K. G. (2014) · NeuroImmunoModulation · doi:10.1159/000362727 · Cited by 16
Change in bone mineral density during adjuvant chemotherapy for early-stage breast cancer
Christensen, C. Ø., Cronin-Fenton, D. P., Frøslev, T., Hermann, A. P., & Ewertz, M. (2016) · Supportive Care in Cancer · doi:10.1007/s00520-016-3250-y · Cited by 16
Guía de prevención y tratamiento de la osteoporosis inducida por glucocorticoides de la Sociedad Española de Medicina Interna
Henríquez, M. S., Díaz Curiel, M., Díez‐Pérez, A., Alonso, C. G., Macías, J. G., Farrerons, J., Rubio, J. F., Mellibovsky, L., Nogués, X., & Hernández, D. (2008) · Revista Clínica Española · doi:10.1157/13115006 · Cited by 18
Bone safety of low-dose glucocorticoids in rheumatic diseases
Saag, K. G. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12446 · Cited by 15
Effect of Denosumab Compared With Risedronate on Bone Strength in Patients Initiating or Continuing Glucocorticoid Treatment
Geusens, P., Bevers, M. S. A. M., van Rietbergen, B., Messina, O. D., Lespessailles, É., Oliveri, B., Chapurlat, R. D., Engelke, K., Chines, A. A., Huang, S., et al. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4551 · Cited by 15
Ibandronate for prevention and treatment of glucocorticoid-induced osteoporosis in rabbits
Zhang, K.-J., Zhang, J., Kang, Z.-K., Xue, X.-M., Kang, J., Li, Y., Dong, H.-N., & Dong-gang, L. (2011) · Rheumatology International · doi:10.1007/s00296-011-2074-9 · Cited by 15
Incidence of Vertebral Fractures in Women with Systemic Lupus Erythematosus After 8 Years of Follow-Up
García‐Carrasco, M., Pinto, C. M., Vázquez, M. D. L. L. L., Méndez‐Martínez, S., Etchegaray‐Morales, I., Montiel-Jarquín, Á. J., Enríquez-Guerra, M. Á., Muñóz‐Guarneros, M., Gálvez-Romero, J. L., Soto-Santillán, P., et al. (2017) · Calcified Tissue International · doi:10.1007/s00223-017-0286-z · Cited by 15
Long-term outcomes of conventional and novel steroid replacement therapy on bone health in primary adrenal insufficiency
Guarnotta, V., Stefano, C. D., & Giordano, C. S. D. S. (2022) · Scientific Reports · doi:10.1038/s41598-022-13506-5 · Cited by 15
Beyond bone mineral density, FRAX-based tailor-made intervention thresholds for therapeutic decision in subjects on glucocorticoid
Yu, S.-F., Chen, J., Chen, Y.-C., Lai, H., Ko, C.-H., Chiu, W.-C., Su, F., Hsu, C., Su, Y., Wu, C., et al. (2017) · Medicine · doi:10.1097/md.0000000000005959 · Cited by 15
Utilidad del Trabecular Bone Score en la valoración del riesgo de fractura osteoporótica
Redondo, L., Puigoriol, E., Rodríguez, J. R., Peris, P., & Kanterewicz, E. (2018) · Revista Clínica Española · doi:10.1016/j.rce.2017.12.005 · Cited by 15
Bisphosphonates: Pharmacology and Use in the Treatment of Osteoporosis
Miller, P. D. (2008) · Elsevier eBooks · doi:10.1016/b978-012370544-0.50076-8 · Cited by 15
Prevention and Treatment of Corticosteroid-Induced Osteoporosis
Iwamoto, J., Takeda, T., & Satō, Y. (2005) · Yonsei Medical Journal · doi:10.3349/ymj.2005.46.4.456 · Cited by 15
German Society of Rheumatology recommendations for management of glucocorticoid-induced osteoporosis
Leipe, J., Holle, J. U., Weseloh, C., Pfeil, A., & Krüger, K. (2021) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-021-01025-z · Cited by 14
Milk kefir therapy improves the skeletal response to resistance exercise in rats submitted to glucocorticoid-induced osteoporosis
de Vasconcelos, R. F., Costa, V., Araújo, B. S., Maia, T. A. C., Dias, R., Vasconcelos, L., Silveira, H., Carneiro, B., Thiers, D., Costa, F. W. G., et al. (2022) · Experimental Gerontology · doi:10.1016/j.exger.2022.111921 · Cited by 15
Glucocorticoid-Induced Osteoporosis
Kennedy, C. C., Παπαϊωάννου, Α., & Adachi, J. D. (2005) · Women s Health · doi:10.2217/17455057.2.1.65 · Cited by 14
Effect of glucocorticoid withdrawal on glucocorticoid inducing bone impairment
Shen, G., Ren, H., Qiu, T., Liang, D., Wei, Q., Tang, J., Zhang, Z., Yao, Z., Zhao, W., & Jiang, X. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.07.036 · Cited by 14
New insights into the biology of glucocorticoid-induced osteoporosis
Lane, N. E., & Yao, W. (2011) · IBMS BoneKEy · doi:10.1138/20110511 · Cited by 15
Long-term safety, efficacy, and patient acceptability of teriparatide in the management of glucocorticoid-induced osteoporosis
Dore, R. K. (2013) · Patient Preference and Adherence · doi:10.2147/ppa.s31067 · Cited by 15
Can adverse effects of glucocorticoid therapy be prevented and treated?
van der Goes, M. C., Strehl, C., Buttgereit, F., Bijlsma, J. W. J., & Jacobs, J. W. G. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1232390 · Cited by 16
Glucocorticoid‐Induced Osteoporosis
Saag, K. G., & Adler, R. A. (2018) · Wiley eBooks · doi:10.1002/9781119266594.ch59 · Cited by 15
Analysis of quality improvement efforts in preventing glucocorticoid-induced osteoporosis
Tory, H. O., Solomon, D. H., & Desai, S. P. (2015) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2014.09.011 · Cited by 13
Recent recommendations on steroid-induced osteoporosis: More targeted, but more complicated
Deal, C. L. (2013) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.80a.11094 · Cited by 13
NHG-Standaard Fractuurpreventie (tweede herziening)
Elders, P. J. M., Dinant, G., van Geel, T. A. C. M., Maartens, L. W. F., Merlijn, T., Geijer, R. M. M., & Geraets, J. J. X. R. (2012) · Pure Amsterdam UMC · Cited by 13
Vertebral fracture risk in glucocorticoid-induced osteoporosis: the role of hypogonadism and corticosteroid boluses
Flórez, H., Hernández‐Rodríguez, J., Carrasco, J. L., Prieto‐González, S., Muxí, Á., Filella, X., Ruiz-Gaspà, S., Gómez-Puerta, J. A., Cid, M. C., Espinosa, G., et al. (2020) · RMD Open · doi:10.1136/rmdopen-2020-001355 · Cited by 14
Abnormal microarchitecture and stiffness in postmenopausal women using chronic inhaled glucocorticoids
Liu, Y., DiMango, E., Bucovsky, M., Agarwal, S., Nishiyama, K. K., Guo, X.-D. E., Shane, E. J., & Stein, E. M. (2018) · Osteoporosis International · doi:10.1007/s00198-018-4591-9 · Cited by 13
Ostéoporose cortico-induite
Briot, K., & Roux, C. (2012) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2012.11.005 · Cited by 15
Actualisation 2014 des recommandations sur la prévention et le traitement de l’ostéoporose cortico-induite
Briot, K., Cortet, B., Roux, C., Fardet, L., Abitbol, V., Bacchetta, J., Buchon, D., Debiais, F., Guggenbuhl, P., Laroche, M., et al. (2014) · Revue du Rhumatisme · doi:10.1016/j.rhum.2014.07.009 · Cited by 15
Glucocorticoid-induced osteoporosis: skeletal manifestations of glucocorticoid use and 2004 Japanese Society for Bone and Mineral Research-proposed guidelines for its management
Soen, S., & Tanaka, Y. (2005) · Modern Rheumatology · doi:10.1007/s10165-005-0391-0 · Cited by 13
In whom and how to prevent glucocorticoid-induced osteoporosis
Adachi, J. D., & Papaioannou, A. (2005) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2005.07.002 · Cited by 13
Evaluation of bone-related mechanical properties in female patients with long-term remission of Cushing's syndrome using quantitative computed tomography–based finite element analysis
Giuliodori, A., Soudah, E., Malouf, J., Martel‐Duguech, L., Amodru, V., Gil, J., Hernández, J. A., Puig‐Domingo, M., Webb, S. M., & Valassi, E. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae004 · Cited by 12
Systemic glucocorticoids in rheumatology
Saag, K. G., & Buttgereit, F. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-09138-1.00054-1 · Cited by 12
Usefulness of the trabecular bone score for assessing the risk of osteoporotic fracture
Redondo, L., Puigoriol, E., Rodríguez, J. R., Peris, P., & Kanterewicz, E. (2018) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2017.12.002 · Cited by 12
Evaluation of risk factors of vertebral fracture in Japanese female patients with glucocorticoid-induced osteoporosis
Mori, Y., Izumiyama, T., Baba, K., Mori, N., Fujii, H., Ishii, T., & Itoi, E. (2020) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-020-01813-4 · Cited by 12
Association of mental disorders and psychotropic medications with bone texture as measured with trabecular bone score
Hafizi, S., Lix, L. M., Hans, D. B., Bolton, J. M., & Leslie, W. D. (2022) · Bone · doi:10.1016/j.bone.2022.116565 · Cited by 11
Urinary deoxypyridinoline is a BMD-independent marker for prevalent vertebral fractures in postmenopausal women treated with glucocorticoid
Kaji, H., Yamauchi, M., Yamaguchi, T., & Sugimoto, T. (2009) · Osteoporosis International · doi:10.1007/s00198-009-1108-6 · Cited by 11
Fracture risk assessment before and after resolution of endogenous hypercortisolism: Is the FRAX® algorithm useful?
Trementino, L., Ceccoli, L., Concettoni, C., Marcelli, G., Michetti, G., Boscaro, M., & Arnaldi, G. (2014) · Journal of Endocrinological Investigation · doi:10.1007/s40618-014-0126-1 · Cited by 11
Prevalence of Vertebral Fractures Independent of BMD and Anticancer Treatment in Patients with Testicular Germ Cell Tumors
Willemse, P.-P. M., Hamdy, N. A. T., van Wulften, L., Tol, A. Q. M. J. V. S.-V., Putter, H., & Osanto, S. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0093 · Cited by 11
Piper Sarmentosum: A New Hope for the Treatment of Osteoporosis
Ramli, E. S. M., Suhaimi, F. H., Ahmad, F., Shuid, A. N., Mohamad, N., & Soelaiman, I. N. (2013) · Current Drug Targets · doi:10.2174/13894501113146660228 · Cited by 11
Empfehlungen der Deutschen Gesellschaft für Rheumatologie zum Management der Glukokortikoid-induzierten Osteoporose
Leipe, J., Holle, J. U., Weseloh, C., Pfeil, A., Krüger, K., & (DGRh), D. K. P. D. D. G. F. R. E. V. (2021) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-021-01028-w · Cited by 12
Does osteopenia warrant treatment?
Simon, J. A. (2005) · Menopause The Journal of The North American Menopause Society · doi:10.1097/01.gme.0000156346.77014.fb · Cited by 11
Guía para la indicación de la densitometría ósea en la valoración del riesgo de fractura y en el control evolutivo de la osteoporosis
Ferrer, A., Estrada, M. D., Borras, A. A., & Espallargues, M. (2009) · Medicina Clínica · doi:10.1016/j.medcli.2008.11.018 · Cited by 11
Glucocorticoid‐induced osteoporosis
Sambrook, P. N. (2008) · International Journal of Rheumatic Diseases · doi:10.1111/j.1756-185x.2008.00391.x · Cited by 11
Osteoporotic fractures in rheumatoid arthritis patients in Argentina: a matched retrospective cohort study
Pierini, F. S., Brom, M., Scolnik, M., Scaglioni, V., Rosa, J. E., & Soriano, E. R. (2021) · Revista Brasileira de Reumatologia · doi:10.1186/s42358-021-00179-3 · Cited by 10
Glucocorticoid-induced osteoporosis: Treatment options and guidelines
Maricic, M. J. (2005) · Current Osteoporosis Reports · doi:10.1007/s11914-005-0024-8 · Cited by 10
Reduction of fibrillar strain-rate sensitivity in steroid-induced osteoporosis linked to changes in mineralized fibrillar nanostructure
Xi, L., Falco, P. D., Barbieri, E., Karunaratne, A., Bentley, L., Esapa, C. T., Davis, G. R., Terrill, N. J., Cox, R., Pugno, N. M., et al. (2019) · Bone · doi:10.1016/j.bone.2019.115111 · Cited by 10
Risk of fracture according to glucocorticoid use after renal biopsy: a nationwide population-based study
Lee, E., Lee, M. J., Park, B., & Park, I. (2020) · Scientific Reports · doi:10.1038/s41598-020-70935-w · Cited by 10
A multiscale study of structural and compositional changes in a natural nanocomposite: Osteoporotic bone with chronic endogenous steroid excess
Xi, L., Zhang, Y., Gupta, H. S., Terrill, N. J., Wang, P., Zhao, T., & Fang, D. (2020) · Bone · doi:10.1016/j.bone.2020.115666 · Cited by 10
Bone Strength/Bone Mass Discrepancy in Glucocorticoid‐Treated Adult Mice
Dubrovsky, A., Nyman, J. S., Uppuganti, S., Chmiel, K. J., Kimmel, D. B., & Lane, N. E. (2020) · JBMR Plus · doi:10.1002/jbm4.10443 · Cited by 10
Risedronate prevents the loss of microarchitecture in glucocorticoid-induced osteoporosis in rats
Carbonare, L. D., Bertoldo, F., Valenti, M. T., Zordan, S., Sella, S., Fassina, A., Turco, G., Realdi, G., Cascio, V. L., & Giannini, S. (2007) · Journal of Endocrinological Investigation · doi:10.1007/bf03350811 · Cited by 10
Glucocorticoid-induced osteoporosis: an overview
Kuchuk, N. O., Hoes, J. N., Bijlsma, J. W. J., & Jacobs, J. W. G. (2014) · International Journal of Clinical Rheumatology · doi:10.2217/ijr.14.24 · Cited by 10
Systemic Lupus Erythematosus
Castrejón, I., Nika, A., Sequeira, W., & Jolly, M. (2017) · Springer eBooks · doi:10.1007/978-3-319-59963-2_6 · Cited by 10
Glucocorticoid-induced osteoporosis preventive care in rheumatology patients
Koller, G., Katz, S. J., Charrois, T. L., & Ye, C. (2019) · Archives of Osteoporosis · doi:10.1007/s11657-019-0570-9 · Cited by 10
Skeletal status assessed by quantitative ultrasound at the calcaneus in females with bronchial asthma on prolonged corticosteroid therapy
Drozdzowska, B. (2004) · Maturitas · doi:10.1016/j.maturitas.2004.09.006 · Cited by 10
Complications Associated with Chronic Steroid Use
Huntoon, M. A. (2007) · Elsevier eBooks · doi:10.1016/b978-1-4160-2392-0.50036-4 · Cited by 10
Glucocorticoids: bad or safe for the bones?
Lems, W. F. (2015) · RMD Open · doi:10.1136/rmdopen-2015-000050 · Cited by 10
Glucocorticoid-induced Osteoporosis
Mazziotti, G., & Giustina, A. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-374602-3.00034-1 · Cited by 9
Effects of combined therapy of alendronate and low-intensity pulsed ultrasound on metaphyseal bone repair after osteotomy in the proximal tibia of glucocorticoid-induced osteopenia rats
Kawano, T., Miyakoshi, N., Kasukawa, Y., Hongo, M., Tsuchie, H., Sato, C., Fujii, M., Suzuki, M., Akagawa, M., Ono, Y., et al. (2017) · Osteoporosis and Sarcopenia · doi:10.1016/j.afos.2017.11.001 · Cited by 9
Hip fractures in the elderly without osteoporosis
Hadjimichael, A. C. (2018) · Journal of Frailty Sarcopenia and Falls · doi:10.22540/jfsf-03-008 · Cited by 9
Inhibition of vascular endothelial growth factor in young adult mice causes low bone blood flow and bone strength with no effect on bone mass in trabecular regions
Lane, N. E., Nyman, J. S., Uppuganti, S., Chaudhari, A. J., Aguirre, J. I., Shidara, K., Liu, X. P., Yao, W., & Kimmel, D. B. (2019) · Bone Reports · doi:10.1016/j.bonr.2019.100210 · Cited by 9
Apoptosis in glucocorticoid-induced bone disease
Weinstein, R. S., & Manolagas, S. C. (2005) · Current Opinion in Internal Medicine · doi:10.1097/01.med.0000162075.95591.9b · Cited by 9
The risk/benefit of inhaled corticosteroids in chronic obstructive pulmonary disease
Bonay, M., Bancal, C., & Crestani, B. (2005) · Expert Opinion on Drug Safety · doi:10.1517/14740338.4.2.251 · Cited by 9
Glucocorticoid‐Induced Bone Disease
Weinstein, R. S. (2013) · Wiley eBooks · doi:10.1002/9781118453926.ch58 · Cited by 9
Sex and age do not modify the association between glucocorticoids and bone mineral density in patients with rheumatoid arthritis: a cross-sectional study
Palmowski, A., Boyadzhieva, Z., Nielsen, S. M., Muche, B., Hermann, S., Boers, M., Bliddal, H., Christensen, R., Wiebe, E., & Buttgereit, F. (2023) · Arthritis Research & Therapy · doi:10.1186/s13075-023-03083-x · Cited by 10
Bone Disease in Newly Diagnosed Lupus Nephritis Patients
Resende, A. L., dos Reis, L. M., Dias, C. B., Custódio, M. R., Jorgetti, V., & Woronik, V. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106728 · Cited by 8
Aqueous extract of pomegranate seed attenuates glucocorticoid-induced bone loss and hypercalciuria in mice: A comparative study with alendronate
Zhang, Y., Shao, J., Wang, Z., Yang, T., Liu, S., Liu, Y., Fan, X., & Ye, W. (2016) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2016.2622 · Cited by 8
Effects of denosumab on rheumatic diseases and refractory glucocorticoid-induced osteoporosis: a prospective study
Ishida, T., Yoshida, S., Fujiki, Y., Hata, K., Kotani, T., & Takeuchi, T. (2021) · Archives of Osteoporosis · doi:10.1007/s11657-021-00899-5 · Cited by 8
Corticosteroids
Lim, S. Y., & Bolster, M. B. (2019) · Springer eBooks · doi:10.1007/978-3-030-16928-2_28 · Cited by 8
The safety of pharmacological treatment options for lupus nephritis
Velo-García, A., Ntatsaki, E., & Isenberg, D. A. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1182496 · Cited by 8
Chapter 58. Glucocorticoid‐Induced Osteoporosis
Weinstein, R. S. (2008) · Primer on the metabolic bone diseases and disorders of mineral metabolism · doi:10.1002/9780470623992.ch58 · Cited by 8
Updated recommendations on the management of glucocorticoid-induced osteoporosis
Orcel, P. (2014) · Joint Bone Spine · doi:10.1016/j.jbspin.2014.08.004 · Cited by 8
Medication-induced fractures: Screening and treatment strategies
Javed, L., Khakwani, A. S., Khan, U., & Humphrey, M. B. (2024) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2024.08.024 · Cited by 7
Reduced Bone Mineral Density and Radial Bone Growth in Young Rabbits Treated with Dexamethasone Eye Drops
Kugelberg, M., Ohlsson, C., & Savendahl, L. S. (2005) · Hormone Research in Paediatrics · doi:10.1159/000084684 · Cited by 7
An update of the Malaysian Clinical Guidance on the management of glucocorticoid-induced osteoporosis, 2015
Yeap, S. S., Hew, F. L., Damodaran, P., Chee, W. S. S., Lee, J. K., Goh, E. M. L., & Chan, S. P. (2017) · Osteoporosis and Sarcopenia · doi:10.1016/j.afos.2017.01.001 · Cited by 7
Stimulation of osteoclast formation and bone resorption by glucocorticoids: Synergistic interactions with the calcium regulating hormones parathyroid hormone and 1,25(OH)2-vitamin D3
Henning, P., Conaway, H. H., & Lerner, U. H. (2022) · Vitamins and hormones · doi:10.1016/bs.vh.2022.04.005 · Cited by 8
Corticosteroid use in chronic dermatologic disorders and osteoporosis
Lupsa, B. C., Insogna, K. L., Micheletti, R. G., & Caplan, A. S. (2021) · International Journal of Women’s Dermatology · doi:10.1016/j.ijwd.2021.07.014 · Cited by 7
Longitudinal practice patterns of prophylaxis of glucocorticoid-induced osteoporosis in patients with polymyalgia rheumatica
Naranjo, A., López, R., Garcia-Magallón, B., Cáceres, L., Francisco, F., Jiménez-Palop, M., & Ojeda-Bruno, S. (2014) · Rheumatology International · doi:10.1007/s00296-014-3014-2 · Cited by 7
Identification of patient profile for treatment
Moon, R. J., & Harvey, N. C. (2014) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2014.04.005 · Cited by 6
Argentine Guidelines for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis in Postmenopausal Women and Men Aged 50 Years and Older
Brance, M. L., Larroudé, M. S., Zamora, N. V., Bagur, A., Graf, C. E., Giacoia, E., Diehl, M., Somma, L. F., Schneeberger, E. E., Salerni, H. H., et al. (2023) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0000000000001951 · Cited by 6
Genistein attenuates glucocorticoid-induced bone deleterious effects through regulation Eph/ephrin expression in aged mice.
Cheng, Y., Wang, W., & Liang, J.-J. (2015) · Europe PMC (PubMed Central) · Cited by 6
Retracted
Are glucocorticoids harmful to bone in early rheumatoid arthritis?
Lems, W. F. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12430 · Cited by 6
El estrés oxidativo como posible diana terapéutica en la osteoporosis asociada al envejecimiento
Portal‐Núñez, S., Dı́ez, A., de la Fuente, M., & Esbrit, P. (2016) · Revista de Osteoporosis y Metabolismo Mineral · doi:10.4321/s1889-836x2016000400007 · Cited by 6
Multiple vertebral fractures associated with glucocorticoid-induced osteoporosis treated with teriparatide followed by kyphosis correction fusion: a case report
Uei, H., Tokuhashi, Y., Maseda, M., Nakahashi, M., & Nakayama, E. (2018) · Osteoporosis International · doi:10.1007/s00198-018-4425-9 · Cited by 6
Glucocorticoid-Induced Osteoporosis
Adler, R. A., Weinstein, R. S., & Saag, K. G. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-415853-5.00049-2 · Cited by 6
Glucocorticoid-induced osteoporosis
Sambrook, P. N. (2011) · Elsevier eBooks · doi:10.1016/b978-0-323-06551-1.00198-6 · Cited by 6
Glucocorticoid-Induced Osteoporosis
Dubrovsky, A., Maricic, M. J., & Lane, N. E. (2020) · Contemporary Endocrinology · doi:10.1007/978-3-319-69287-6_21 · Cited by 6
Notable Difference between the Development of Vertebral Fracture and Osteonecrosis of the Femoral Head in Patients Treated with High-dose Glucocorticoids for Systemic Rheumatic Diseases
Kameda, H., Amano, K., Nagasawa, H., Ogawa, H., Sekiguchi, N., Takei, H., Suzuki, K., & Takeuchi, T. (2009) · Internal Medicine · doi:10.2169/internalmedicine.48.2414 · Cited by 6
A narrative review of the role of glucocorticoid receptors in prostate cancer: developments in last 5 years
Zhou, F., Shi, Y. X., Zhao, G., Aufderklamm, S., Murray, K. S., & Jin, B. (2022) · Translational Andrology and Urology · doi:10.21037/tau-22-501 · Cited by 6
Prise en charge de l’ostéoporose cortisonique
Orcel, P. (2006) · La Presse Médicale · doi:10.1016/s0755-4982(06)74853-9 · Cited by 6
Radiofrequency Echographic Multi Spectrometry (REMS) for the evaluation of bone health in systemic lupus erythematosus (SLE)
Diz-Lopes, M., Orsolini, G., Galvagni, I., Rotta, D., Dartizio, C., Benini, C., Fassio, A., Gatti, D., Viapiana, O., Rossini, M., et al. (2025) · Osteoporosis International · doi:10.1007/s00198-025-07824-3 · Cited by 5
EndoCompass project: research roadmap for calcium and bone endocrinology
Jähn, K., Zibar, K., Anastasilakis, A. D., Bertocchio, J., Brandi, M. L., Faßnacht, M., Cheung, M., Gevers, E. F., Gittoes, N. J. L., Mäkitie, O., et al. (2025) · European Journal of Endocrinology · doi:10.1093/ejendo/lvaf064 · Cited by 5
Grundlagen und Management der glukokortikoidinduzierten Osteoporose
Willenberg, H. S., & Lehnert, H. (2008) · Der Internist · doi:10.1007/s00108-008-2118-8 · Cited by 5
Bone involvement in exogenous hypercortisolism
SINIGAGLIA, L., Mazzocchi, D., & VARENNA, M. (2008) · Journal of Endocrinological Investigation · doi:10.1007/bf03346372 · Cited by 5
Management of glucocorticoid‐induced osteoporosis: What is new?
Compston, J. E. (2019) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.13680 · Cited by 5

Authors: Van Staa, T. P., Laan, R. F., Barton, I. P., Cohen, S., Reid, D. M., & Cooper, C.
Affiliations: Procter & Gamble (United Kingdom) (GB)
University of Aberdeen (GB)
University of Southampton (GB)
ORCID: Laan, R. F.
Cohen, S.
Reid, D. M.
Cooper, C.
Venue: Arthritis & Rheumatism
Publisher: Wiley
Published: 2003-11
Volume: 48
Issue: 11
Pages: 3224-3229
ISSN: 0004-3591 (ISSN-L)
1529-0131
DOI: 10.1002/art.11283
OpenAlex: W1978136096
Cited by: 559
References: 29
Citations by year: 2026: 6 · 2025: 14 · 2024: 11 · 2023: 13 · 2022: 21 · 2021: 27 · 2020: 28 · 2019: 30 · 2018: 36 · 2017: 30 · 2016: 28 · 2015: 36 · 2014: 29 · 2013: 29 · 2012: 23
FWCI: 21.19
Type: journal article
Language: en
Open access: closed
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor, 3 d)
Locations: Arthritis & Rheumatism (publishedVersion)
PubMed (publishedVersion)
Research Explorer (The University of Manchester) (publishedVersion)
ePrints Soton (University of Southampton) (submittedVersion)
Radboud Repository (Radboud University) (submittedVersion)
Topics: Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
Health Sciences › Medicine › Oncology › Bone health and treatments
Keywords: vertebral fractures, oral corticosteroids, bone mineral density, fracture risk prediction, risedronate, postmenopausal women, glucocorticoid dose, osteoporosis, lumbar spine bone mineral density, T-score thresholds
MeSH terms: Administration, Oral, Adolescent, Adult, Aged, Aged, 80 and over, Double-Blind Method, Female, Femur Neck, Glucocorticoids, Humans, Lumbar Vertebrae, Male, Middle Aged, Prednisone, Risk, Risk Factors, Absorptiometry, Photon, Bone Density, Osteoporosis, Postmenopausal, Spinal Fractures, Postmenopause

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks